Search

everythinglearnresearchcommunity

for

Search:↓

ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.

Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.

MK-5108 is safe and shows potential against tumors, especially alone.

NCSTN gene mutation causes abnormal skin cell differentiation and more inflammation, contributing to Hidradenitis Suppurativa.

New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.

New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

ALRN-6924 may prevent hair loss caused by chemotherapy.

Dauricine may help treat certain brain cancers by reducing cancer cell growth and promoting cell death.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Some new isatin compounds could be strong cancer-fighting drugs because they fit well in cancer-related proteins and have good drug-like properties.

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

Chemotherapy-induced hair loss is a major concern, but various treatments show promise in preventing and reversing it.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Targeting ornithine decarboxylase can help prevent skin cancer.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Tadalafil and Finasteride may help treat aggressive melanoma.

Cialis and Finasteride could be repurposed to treat aggressive melanoma.

Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

JAK inhibitors have therapeutic potential but pose significant risks, requiring careful monitoring.

Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Blocking DKK1 with siRNA can improve hair growth.

JAK inhibitors help treat some diseases but may increase risks of blood clots and cancer in certain patients.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.